-
Article
Circulating tumor cells in Waldenström macroglobulinemia
-
Article
Open AccessFinal results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study
We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five year...
-
Chapter
Waldenström-Makroglobulinämie
Die Waldenström-Makroglobulinämie (WM) ist eine seltene, ausgeprägte klinisch-pathologische indolente lymphoproliferative B-Zell-Erkrankung, die erstmals 1944 von Jan Gosta Waldenström beschrieben wurde. Der z...
-
Article
SARS-CoV-2 infection in patients with primary central nervous system lymphoma
Cancer patients may be at higher risk for severe coronavirus infectious disease-19 (COVID-19); however, the outcome of Primary Central Nervous System Lymphoma (PCNSL) patients with SARS-CoV-2 infection has not...
-
Article
Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard?
Progressive multifocal leukoencephalopathy (PML) is a very rare and opportunistic encephalitis caused by JC polyomavirus that is linked to profound immunosuppression and is usually fatal unless immune function...
-
Article
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled in...
-
Chapter
Waldenstrom’s Macroglobulinemia
Waldenström’s macroglobulinemia (WM) is a rare, distinct clinicopathological indolent B-cell lymphoproliferative disorder, first described in 1944 by Jan Gosta Waldenström (Incipient myelomatosis or essential ...
-
Article
Open AccessObinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
GREEN (NCT01905943) is a nonrandomized, open-label, single-arm, phase 3b study investigating the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in chronic lymphocytic leukemia (C...
-
Article
How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy
Waldenström macroglobulinemia (WM) is a rare lymphoproliferative disorder. Up to now, therapeutic choice was not influenced by the biological characteristics of the disease. Here, we will review how recent adv...
-
Article
Open AccessPrevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies
Posaconazole is a triazole antifungal used to prevent invasive fungal infections (IFIs) in patients receiving chemotherapy or haemotopoietic stem cell transplantation. Due to highly variable bioavailability of...
-
Chapter
Treatment Recommendations in Waldenström Macroglobulinemia
Waldenström’s macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as ...
-
Chapter
Immunotherapy in Waldenstrom’s Macroglobulinemia
The use of anti-CD20 monoclonal antibody is a standard of care in Waldenström’s macroglobulinemia (WM) patients in first line and in relapse. The combination of anti-CD20 monoclonal antibody with chemotherapy ...
-
Chapter
Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains
Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder characterized by bone marrow infiltration of lymphoplasmacytic cells along with production of an IgM monoclonal protein in t...
-
Article
Open AccessRecommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia
Hairy cell leukaemia (HCL) is a rare haematological malignancy, with approximately 175 new incident cases in France. Diagnosis is based on a careful examination of the blood smear and immunophenoty** of the ...
-
Article
Open AccessNorovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia
Norovirus infection is increasingly recognized as an important cause of persistent gastroenteritis in immunocompromised hosts and can be a potential cause of morbidity in these populations.
-
Chapter
Waldenström’s Macroglobulinemia
The diagnostic concept of Waldenström’s macroglobulinemia (WM) has changed dramatically since Jan Waldenström originally reported two patients with a syndrome of oronasal bleeding, lymphadenopathy, an elevated...
-
Article
Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases
To better characterize ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue (MZL-MALT), we analyzed the clinical and pathologic features of 23 patients (11 men, 12 women, median age 66 ye...
-
Chapter and Conference Paper
Identification of Prognostic Factors in Post-Transplant Lymphoproliferative Disorders
Organ transplantations can lead to post-transplant lymphoproliferative disorders (PT-LPDs) as a result of immunosuppressive therapy. PT-LPDs clearly differ from non-Hodgkin’s lymphomas occurring in immunocompe...
-
Article
Alternative origin of p13MTCP1-encoding transcripts in mature T-cell proliferations with t(X;14) translocations
The MTCP1 gene is involved in the t(X;14)(q28;q11) translocation associated with T-cell prolymphocytic leukemia and related conditions. This gene is unusual in that it codes for two distinct proteins: a small mit...
-
Chapter and Conference Paper
Sequential Chemotherapy with Mitoxantrone, Etoposide and Cytarabine for Previously Treated Acute Myeloid Leukemia: EMA 86 Regimen
EMA 86 regimen, associating mitoxantrone, 12 mg/m2/day on days 1–3, etoposide, 200 mg/m2/day as a continuous infusion on days 8–10 and cytarabine, 500 mg/m2/day as a continuous infusion on days 1–3 and 8–10, was ...
